I am a postdoctoral researcher in medicinal peptide chemistry specialising in the design and synthesis of peptidomimetics to modulate protein-protein interactions in cancer. My current work focuses on the MYBL2-MuvB transcriptional complex, a key oncogenic driver in aggressive prostate cancer, where I develop conformationally constrained macrocyclic and turn-mimetic ligands to disrupt this interaction and suppress tumour-promoting gene expression.
 
My research integrates rational molecular design, solid-phase peptide and peptidomimetic synthesis, and advanced biophysical and computational methods to optimise binding, stability, and cellular activity. I work at the interface of chemistry and biology, using structure-guided design, docking, and SAR analysis to drive the development of first-in-class inhibitors of challenging intracellular targets.
 
Alongside my oncology work, I remain actively involved in the development of cyclic peptide-based antibiotics targeting multidrug-resistant ESKAPE pathogens. This includes the synthesis and optimisation of macrocyclic antimicrobial peptides with improved therapeutic windows, informed by NMR-derived structural data and machine-learning-guided SAR models.
 
Across both cancer and infectious-disease programs, my broader research vision is to build scalable chemical platforms for the discovery of biologically active macrocycles and peptidomimetics that can access targets beyond the reach of traditional small molecules. My work is driven by the goal of translating rigorous chemical innovation into new therapies for diseases with high unmet clinical need.